Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)
October 30, 2019 7:45 AM EDT
Cowen analyst Boris peaker raised the price target on Seattle Genetics (NASDAQ: SGEN) to $100.00 (from $80.00) while maintaining a Market Perform rating.... More
October 30, 2019 7:44 AM EDT
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $140.00 price target on Seattle Genetics (NASDAQ: SGEN). With ongoing clinical momentum and against the backdrop of strong Adcetris sales, Fein believes Seattle Genetics is building a powerful value-driving structure upon its various assets.... More
October 30, 2019 6:31 AM EDT
RBC Capital analyst Kennen MacKay lowered the price target on Seattle Genetics (NASDAQ: SGEN) to $107.00 (from $109.00) while maintaining a Outperform rating.... More
October 29, 2019 4:14 PM EDT
Seattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.55), $0.19 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $213.26 million versus the consensus estimate of $211.83 million.
We are executing on our vision of becoming a multi-product global oncology company, recently achieving several important milestones across our late-stage pipeline, said Clay Siegall, Ph.D., President and Chief... More
